Výsledky vyhledávání

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis

Publikováno v: CELL METABOLISM
CELL METABOLISM, 2020, ⟨10.1016/j.cmet.2020.06.005⟩
Cell metabolism, vol 32, iss 5
Cell Metabolism
Cell Metabolism, 2020, 32 (5), pp.901. ⟨10.1016/j.cmet.2020.10.015⟩
Cell Metab
Cell Metabolism, Elsevier, 2020, 32 (5), pp.901. ⟨10.1016/j.cmet.2020.10.015⟩

Dysregulation of the gut microbiome has been implicated in the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic capacity of this association, we compared stool microbiomes across

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c88e5329e9d4a4c25150760f59ca5c
https://hal.archives-ouvertes.fr/hal-02902518

Zobrazit plný text záznamu

Prospective, Same-day, Direct Comparison of CAP With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Standard

Autor: Sirlin, C. B., Loomba, R., Caussy, C., Brissot, J., Singh, S., Bassirian, S., Hernandez, C., Bettencourt, R., Rizo, E., Richards, L.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, ⟨10.1016/j.cgh.2019.11.060⟩
Clinical Gastroenterology and Hepatology
Clinical Gastroenterology and Hepatology, In press, 18 (8), pp.1842. ⟨10.1016/j.cgh.2019.11.060⟩
Clinical Gastroenterology and Hepatology, WB Saunders, In press, 18 (8), pp.1842. ⟨10.1016/j.cgh.2019.11.060⟩

International audience; BACKGROUND & AIMS: Controlled attenuation parameter (CAP) measurements using M probe have been reported to be lower than those of the XL-probe in detection of hepatic steatosis. However, there has been no direct comparison of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::61ebd7960db6c8709f13cef73921fc4d
https://hal.archives-ouvertes.fr/hal-02465737

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease

Autor: Harlow, KE, Africa, JA, Wells, A, Belt, PH, Behling, CA, Jain, AK, Molleston, JP, Newton, KP, Rosenthal, P, Vos, MB, Xanthakos, SA, Lavine, JE, Schwimmer, JB, Abrams, SH, Barlow, S, Himes, R, Krisnamurthy, R, Maldonado, L, Mahabir, R, Carr, A, Bernstein, K, Bramlage, K, Cecil, K, DeVore, S, Kohli, R, Lake, K, Podberesky, D, Towbin, A, Behr, G, Lefkowitch, JH, Mencin, A, Reynoso, E, Alazraki, A, Cleeton, R, Cordero, M, Hernandez, A, Karpen, S, Munos, JC, Raviele, N, Bozic, M, Cummings, OW, Klipsch, A, Ragozzino, E, Sandrasegaran, K, Subbarao, G, Walker, L, Kafka, K, Scheimann, A, Ito, J, Fishbein, MH, Mohammad, S, Rigsby, C, Sharda, L, Whitington, PF, Cattoor, T, Derdoy, J, Freebersyser, J, King, D, Lai, J, Osmack, P, Siegner, J, Stewart, S, Torretta, S, Wriston, K, Baker, SS, Lopez-Graham, D, Williams, S, Zhu, L, Awai, H, Bross, C, Collins, J, Durelle, J, Middleton, M, Paiz, M, Sirlin, C, Ugalde-Nicalo, P, Villarreal, MD, Aouizerat, B, Courtier, J, Ferrell, LD, Feier, N, Gill, R, Langlois, C, Perito, ER, Tsai, P, Cooper, K, Horslen, S, Hsu, E, Murray, K, Otto, R, Yeh, M, Young, M, Brunt, EM, Fowler, K

Publikováno v: Harlow, KE; Africa, JA; Wells, A; Belt, PH; Behling, CA; Jain, AK; et al.(2018). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. Journal of Pediatrics, 198, 76-83.e2. doi: 10.1016/j.jpeds.2018.02.038. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2386g6hb

© 2018 Elsevier Inc. Objective: To determine the percentage of children with nonalcoholic fatty liver disease (NAFLD) in whom intervention for low-density lipoprotein cholesterol or triglycerides was indicated based on National Heart, Lung, and Bloo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ffa40065e58a3bc88611368ea48fc9e6
http://www.escholarship.org/uc/item/2386g6hb

Zobrazit plný text záznamu

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

Publikováno v: Brunt, E; Aishima, S; Clavien, PA; Fowler, K; Goodman, Z; Gores, G; et al.(2018). cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 68(1), 113-126. doi: 10.1002/hep.29789. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2570j08b

© 2018 by the American Association for the Study of Liver Diseases. Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::dda53f491e3b986edd9d335aef4e0114
http://www.escholarship.org/uc/item/2570j08b

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání